Skip to main content
Erschienen in: American Journal of Clinical Dermatology 3/2003

01.03.2003 | Therapy in Practice

HIV-Associated Pruritus

Etiology and Management

verfasst von: Fiza Singh, Dr Donald Rudikoff

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 3/2003

Einloggen, um Zugang zu erhalten

Abstract

With the advent of highly active antiretroviral therapy (HAART), life-threatening opportunistic infection has become less common in patients with HIV infection and longevity has increased dramatically. With increased longevity, the problems of living with a chronic disease have become more prominent in this patient population. Disorders such as fat redistribution and metabolic abnormalities can result from antiviral medications and from HIV disease itself. Pruritus is one of the most common symptoms encountered in patients with HIV.
The spectrum of skin diseases in such patients encompasses dermatoses of diverse etiologies; a few are peculiar to patients with HIV while others are not. Some of these conditions may cause severe and sometimes intractable pruritus that provokes scratching, picking, disfigurement, sleep loss, and significant psychological stress. Moreover, the expense of ongoing medical treatments can be daunting. Skin rash can sometimes be the initial presentation of HIV infection or serve as a harbinger of disease progression.
Causes of pruritus include skin infections, infestations, papulosquamous disorders, photodermatitis, xerosis, drug reactions, and occasionally lymphoproliferative disorders. Drug eruptions are particularly common in patients who are HIV positive, presumably as a result of immune dysregulation, altered drug metabolism, and polypharmacy. Itching can also result from systemic diseases such as chronic renal failure, liver disease, or systemic lymphoma.
Workup of pruritus should include a careful examination of the skin, hair, nails, and mucous membranes to establish a primary dermatologic diagnosis. If no dermatologic cause is found, a systemic cause or medicationrelated etiology should be sought. Idiopathic HIV pruritus is a diagnosis of exclusion and should only be considered when a specific diagnosis cannot be established.
The management of HIV-associated pruritus should be directed at the underlying condition. Phototherapy has been found to be useful in the treatment of several HIV-associated dermatoses and idiopathic pruritus as well. Unfortunately, some of the treatments that have been suggested for patients with HIV are anecdotal or based on small uncontrolled studies. The last decade has seen a surge in the utilization of HAART which, to some degree, reconstitutes the immune system and ameliorates some dermatologic diseases. On the other hand, some skin diseases flare temporarily when HAART is started. Unless frank drug allergy is suspected, HAART does not need to be stopped.
Fußnoten
1
Use of tradenames is for product identification only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Wong T, Chiasson MA, Reggy A, et al. Antiretroviral therapy and declining AIDS mortality in New York City. J Urban Health 2000; 77: 492–500PubMedCrossRef Wong T, Chiasson MA, Reggy A, et al. Antiretroviral therapy and declining AIDS mortality in New York City. J Urban Health 2000; 77: 492–500PubMedCrossRef
2.
Zurück zum Zitat Gelfand JM, Rudikoff D. Evaluation and treatment of itching in HIV-infected patients. Mt Sinai J Med 2001; 68: 298–308PubMed Gelfand JM, Rudikoff D. Evaluation and treatment of itching in HIV-infected patients. Mt Sinai J Med 2001; 68: 298–308PubMed
4.
Zurück zum Zitat Friedler S, Parisi MT, Waldo E, et al. Atypical cutaneous lymphoproliferative disorder in patients with HIV infection. Int J Dermatol 1999; 38: 111–118PubMedCrossRef Friedler S, Parisi MT, Waldo E, et al. Atypical cutaneous lymphoproliferative disorder in patients with HIV infection. Int J Dermatol 1999; 38: 111–118PubMedCrossRef
5.
Zurück zum Zitat Smith RJ, Skelton HG, Yeager J, et al. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. Clin Exp Dermatol 1997; 22: 118–123PubMedCrossRef Smith RJ, Skelton HG, Yeager J, et al. Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. Clin Exp Dermatol 1997; 22: 118–123PubMedCrossRef
6.
Zurück zum Zitat Gajewski LK, Grimone AJ, Melbourne KM, et al. Characterization of rash with indinavir in a national patient cohort. Ann Pharmacother 1999; 33: 17–21PubMedCrossRef Gajewski LK, Grimone AJ, Melbourne KM, et al. Characterization of rash with indinavir in a national patient cohort. Ann Pharmacother 1999; 33: 17–21PubMedCrossRef
7.
Zurück zum Zitat Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 2001; 33: 115–119PubMedCrossRef Szczech LA. Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course, and management. Clin Infect Dis 2001; 33: 115–119PubMedCrossRef
8.
Zurück zum Zitat Bonacini M. Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections. Dig Liver Dis 2000; 32: 621–625PubMedCrossRef Bonacini M. Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections. Dig Liver Dis 2000; 32: 621–625PubMedCrossRef
9.
Zurück zum Zitat Prakash M, Poreddy V, Tiyyagura L, et al. Jaundice and hepatocellular damage associated with nevirapine therapy. Am J Gastroenterol 2001; 96: 1571–1574PubMedCrossRef Prakash M, Poreddy V, Tiyyagura L, et al. Jaundice and hepatocellular damage associated with nevirapine therapy. Am J Gastroenterol 2001; 96: 1571–1574PubMedCrossRef
10.
Zurück zum Zitat Lambert M. Thyroid dysfunction in HIV infection. Baillieres Clin Endocrinol Metab 1994; 8: 825–835PubMedCrossRef Lambert M. Thyroid dysfunction in HIV infection. Baillieres Clin Endocrinol Metab 1994; 8: 825–835PubMedCrossRef
11.
Zurück zum Zitat Gabarre J, Raphael M, Lepage E, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med 2001; 111: 704–711PubMedCrossRef Gabarre J, Raphael M, Lepage E, et al. Human immunodeficiency virus-related lymphoma: relation between clinical features and histologic subtypes. Am J Med 2001; 111: 704–711PubMedCrossRef
12.
Zurück zum Zitat Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860PubMedCrossRef Palella Jr FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853–860PubMedCrossRef
13.
Zurück zum Zitat Handa S, Bingham JS. Dermatological immune restoration syndrome: does it exist? J Eur Acad Dermatol Venereol 2001; 15: 430–432PubMedCrossRef Handa S, Bingham JS. Dermatological immune restoration syndrome: does it exist? J Eur Acad Dermatol Venereol 2001; 15: 430–432PubMedCrossRef
14.
Zurück zum Zitat Bachmeyer C, Cordier F, Cazier A, et al. Eosinophilic folliculitis associated with AIDS after antiretroviral tri-therapy. Presse Med 1999; 28: 2226PubMed Bachmeyer C, Cordier F, Cazier A, et al. Eosinophilic folliculitis associated with AIDS after antiretroviral tri-therapy. Presse Med 1999; 28: 2226PubMed
15.
Zurück zum Zitat Shimizu S, Chen KR, Tagami H, et al. Mucocutaneous manifestations in Japanese HIV-positive hemophiliacs. Dermatology 2000; 201: 321–325PubMedCrossRef Shimizu S, Chen KR, Tagami H, et al. Mucocutaneous manifestations in Japanese HIV-positive hemophiliacs. Dermatology 2000; 201: 321–325PubMedCrossRef
16.
Zurück zum Zitat Arlian LG, Estes SA, Vyszenski-Moher DL. Prevalence of Sarcoptes scabiei in the homes and nursing homes of scabietic patients. J Am Acad Dermatol 1988; 19: 806–811PubMedCrossRef Arlian LG, Estes SA, Vyszenski-Moher DL. Prevalence of Sarcoptes scabiei in the homes and nursing homes of scabietic patients. J Am Acad Dermatol 1988; 19: 806–811PubMedCrossRef
17.
Zurück zum Zitat Dourmishev A, Serafimova D, Dourmishev L. Efficacy and tolerance of oral ivermectin in scabies. J Eur Acad Dermatol Venereol 1998; 11: 247–251PubMedCrossRef Dourmishev A, Serafimova D, Dourmishev L. Efficacy and tolerance of oral ivermectin in scabies. J Eur Acad Dermatol Venereol 1998; 11: 247–251PubMedCrossRef
18.
Zurück zum Zitat Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236–240PubMedCrossRef Usha V, Gopalakrishnan Nair TV. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42: 236–240PubMedCrossRef
19.
Zurück zum Zitat Burkhart CN, Burkhart CG. Ivermectin: a few caveats are warranted before initiating therapy for scabies. Arch Dermatol 1999; 135: 1549–1550PubMedCrossRef Burkhart CN, Burkhart CG. Ivermectin: a few caveats are warranted before initiating therapy for scabies. Arch Dermatol 1999; 135: 1549–1550PubMedCrossRef
20.
Zurück zum Zitat Cone LA, Woodard DR, Byrd RG, et al. A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS. J Infect Dis 1992; 165: 638–643PubMedCrossRef Cone LA, Woodard DR, Byrd RG, et al. A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS. J Infect Dis 1992; 165: 638–643PubMedCrossRef
21.
Zurück zum Zitat Raviglione MC, Mariuz P, Pablos-Mendez A, et al. High Staphylococcus aureus nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. Am J Infect Control 1990; 18: 64–69PubMedCrossRef Raviglione MC, Mariuz P, Pablos-Mendez A, et al. High Staphylococcus aureus nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. Am J Infect Control 1990; 18: 64–69PubMedCrossRef
22.
Zurück zum Zitat Holbrook KA, Klein RS, Hartel D, et al. Staphylococcus aureus nasal colonization in HIV-seropositive and HIV-seronegative drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 301–306PubMedCrossRef Holbrook KA, Klein RS, Hartel D, et al. Staphylococcus aureus nasal colonization in HIV-seropositive and HIV-seronegative drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 301–306PubMedCrossRef
23.
Zurück zum Zitat Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis 1999; 180: 896–899PubMedCrossRef Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis 1999; 180: 896–899PubMedCrossRef
24.
Zurück zum Zitat Cockerell CJ. Seborrheic dermatitis-like and atopic dermatitis-like eruptions in HIV-infected patients. Clin Dermatol 1991; 9: 49–51PubMedCrossRef Cockerell CJ. Seborrheic dermatitis-like and atopic dermatitis-like eruptions in HIV-infected patients. Clin Dermatol 1991; 9: 49–51PubMedCrossRef
25.
Zurück zum Zitat Rudikoff D. The relationship between HIV infection and atopic dermatitis. Curr Allergy Asthma Rep 2002; 2: 275–281PubMedCrossRef Rudikoff D. The relationship between HIV infection and atopic dermatitis. Curr Allergy Asthma Rep 2002; 2: 275–281PubMedCrossRef
26.
Zurück zum Zitat Lin RY, Lazarus TS. Asthma and related atopic disorders in outpatients attending an urban HIV clinic. Ann Allergy Asthma Immunol 1995; 74: 510–515PubMed Lin RY, Lazarus TS. Asthma and related atopic disorders in outpatients attending an urban HIV clinic. Ann Allergy Asthma Immunol 1995; 74: 510–515PubMed
27.
Zurück zum Zitat Lin RY. Chronic diffuse dermatitis and hyper-IgE in HIV infection. Acta Derm Venereol 1988; 68: 486–491PubMed Lin RY. Chronic diffuse dermatitis and hyper-IgE in HIV infection. Acta Derm Venereol 1988; 68: 486–491PubMed
28.
Zurück zum Zitat Paganelli R, Scala E, Mezzaroma I, et al. Immunologic aspects of hyperimmunoglobulinemia E-like syndrome in patients with AIDS. J Allergy Clin Immunol 1995; 95: 995–1003PubMedCrossRef Paganelli R, Scala E, Mezzaroma I, et al. Immunologic aspects of hyperimmunoglobulinemia E-like syndrome in patients with AIDS. J Allergy Clin Immunol 1995; 95: 995–1003PubMedCrossRef
29.
Zurück zum Zitat Nissen D, Nolte H, Permin H, et al. Evaluation of IgE-sensitization to fungi in HIV-positive patients with eczematous skin reactions. Ann Allergy Asthma Immunol 1999; 83: 153–159PubMedCrossRef Nissen D, Nolte H, Permin H, et al. Evaluation of IgE-sensitization to fungi in HIV-positive patients with eczematous skin reactions. Ann Allergy Asthma Immunol 1999; 83: 153–159PubMedCrossRef
30.
Zurück zum Zitat Solinger AM, Hess EV. Rheumatic diseases and AIDS: is the association real? J Rheumatol 1993; 20: 678–683PubMed Solinger AM, Hess EV. Rheumatic diseases and AIDS: is the association real? J Rheumatol 1993; 20: 678–683PubMed
31.
Zurück zum Zitat Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndromeassociated psoriasis and Reiter’s syndrome. Arch Dermatol 1987; 123: 1622–1632PubMedCrossRef Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndromeassociated psoriasis and Reiter’s syndrome. Arch Dermatol 1987; 123: 1622–1632PubMedCrossRef
32.
Zurück zum Zitat Morar N, Dlova N, Gupta AK, et al. Erythroderma: a comparison between HIV positive and negative patients. Int J Dermatol 1999; 38: 895–900PubMedCrossRef Morar N, Dlova N, Gupta AK, et al. Erythroderma: a comparison between HIV positive and negative patients. Int J Dermatol 1999; 38: 895–900PubMedCrossRef
33.
Zurück zum Zitat Mallon E, Young D, Bunce M, et al. HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol 1998; 139: 527–533PubMedCrossRef Mallon E, Young D, Bunce M, et al. HLA-Cw*0602 and HIV-associated psoriasis. Br J Dermatol 1998; 139: 527–533PubMedCrossRef
34.
Zurück zum Zitat Fischer T, Schworer H, Vente C, et al. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. AIDS 1999; 13: 628–629PubMedCrossRef Fischer T, Schworer H, Vente C, et al. Clinical improvement of HIV-associated psoriasis parallels a reduction of HIV viral load induced by effective antiretroviral therapy. AIDS 1999; 13: 628–629PubMedCrossRef
35.
Zurück zum Zitat Duvic M, Crane MM, Conant M, et al. Zidovudine improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol 1994; 130: 447–451PubMedCrossRef Duvic M, Crane MM, Conant M, et al. Zidovudine improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol 1994; 130: 447–451PubMedCrossRef
36.
Zurück zum Zitat Kaplan MH, Sadick NS, Wieder J, et al. Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis. J Am Acad Dermatol 1989; 20: 76–82PubMedCrossRef Kaplan MH, Sadick NS, Wieder J, et al. Antipsoriatic effects of zidovudine in human immunodeficiency virus-associated psoriasis. J Am Acad Dermatol 1989; 20: 76–82PubMedCrossRef
37.
Zurück zum Zitat Ruzicka T, Froschl M, Hohenleutner U, et al. Treatment of HIV-induced retinoidresistant psoriasis with zidovudine. Lancet 1987; II: 1469–1470CrossRef Ruzicka T, Froschl M, Hohenleutner U, et al. Treatment of HIV-induced retinoidresistant psoriasis with zidovudine. Lancet 1987; II: 1469–1470CrossRef
38.
Zurück zum Zitat Akaraphanth R, Lim HW. HIV, UV and immunosuppression. Photdermatol Photoimmunol Photomed 1999; 15: 28–31CrossRef Akaraphanth R, Lim HW. HIV, UV and immunosuppression. Photdermatol Photoimmunol Photomed 1999; 15: 28–31CrossRef
39.
Zurück zum Zitat Morrey JD, Bourn SM, Bunch TD, et al. In vivo activation of human immunodeficiency virus type 1 long terminal repeat by UV type A (UV-A) light plus psoralen and UV-B light in the skin of transgenic mice. J Virol 1991; 65: 5045–5051PubMed Morrey JD, Bourn SM, Bunch TD, et al. In vivo activation of human immunodeficiency virus type 1 long terminal repeat by UV type A (UV-A) light plus psoralen and UV-B light in the skin of transgenic mice. J Virol 1991; 65: 5045–5051PubMed
40.
Zurück zum Zitat Gelfand JM, Rudikoff D, Lebwohl M, et al. Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. Arch Dermatol 1998; 134: 940–945PubMedCrossRef Gelfand JM, Rudikoff D, Lebwohl M, et al. Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. Arch Dermatol 1998; 134: 940–945PubMedCrossRef
41.
Zurück zum Zitat Ranki A, Puska P, Mattinen S, et al. Effect of PUVA on immunologic and virologic findings in HIV-infected patients. J Am Acad Dermatol 1991; 24: 404–410PubMedCrossRef Ranki A, Puska P, Mattinen S, et al. Effect of PUVA on immunologic and virologic findings in HIV-infected patients. J Am Acad Dermatol 1991; 24: 404–410PubMedCrossRef
42.
Zurück zum Zitat Pechere M, Yerly S, Lemonnier E, et al. Impact of PUVA therapy on HIV viremia: a pilot study. Dermatology 1997; 195: 84–85PubMedCrossRef Pechere M, Yerly S, Lemonnier E, et al. Impact of PUVA therapy on HIV viremia: a pilot study. Dermatology 1997; 195: 84–85PubMedCrossRef
43.
Zurück zum Zitat Akaraphanth R, Lim HW. HIV, UV and immunosuppression. Photodermatol Photoimmunol Photomed 1999; 15: 28–31PubMedCrossRef Akaraphanth R, Lim HW. HIV, UV and immunosuppression. Photodermatol Photoimmunol Photomed 1999; 15: 28–31PubMedCrossRef
44.
Zurück zum Zitat Morison WL. PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Photochem Photobiol 1996; 64: 267–268PubMedCrossRef Morison WL. PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Photochem Photobiol 1996; 64: 267–268PubMedCrossRef
45.
Zurück zum Zitat Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA follow-up study. N Engl J Med 1997; 336: 1041–1045PubMedCrossRef Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA): the PUVA follow-up study. N Engl J Med 1997; 336: 1041–1045PubMedCrossRef
46.
Zurück zum Zitat Buccheri L, Katchen BR, Karter AJ, et al. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997; 133: 711–715PubMedCrossRef Buccheri L, Katchen BR, Karter AJ, et al. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol 1997; 133: 711–715PubMedCrossRef
47.
Zurück zum Zitat Maurer TA, Zackheim HS, Tuffanelli L, et al. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994; 31: 372–375PubMedCrossRef Maurer TA, Zackheim HS, Tuffanelli L, et al. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994; 31: 372–375PubMedCrossRef
48.
Zurück zum Zitat Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 1987; 17: 1055–1056PubMedCrossRef Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 1987; 17: 1055–1056PubMedCrossRef
49.
Zurück zum Zitat Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole: a potentially hazardous combination. Clin Exp Dermatol 1990; 15: 358–360PubMedCrossRef Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole: a potentially hazardous combination. Clin Exp Dermatol 1990; 15: 358–360PubMedCrossRef
50.
Zurück zum Zitat Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol 2001; 40: 530–534PubMedCrossRef Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol 2001; 40: 530–534PubMedCrossRef
51.
Zurück zum Zitat Reisler K. High hepatotoxicity rate seen among HAART patients. Aids Alert 2001; 16: 118–119PubMed Reisler K. High hepatotoxicity rate seen among HAART patients. Aids Alert 2001; 16: 118–119PubMed
52.
Zurück zum Zitat Aboulafia DM, Bundow D, Wilske K, et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75: 1093–1098PubMedCrossRef Aboulafia DM, Bundow D, Wilske K, et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000; 75: 1093–1098PubMedCrossRef
53.
Zurück zum Zitat Matis WL, Triana A, Shapiro R, et al. Dermatologic findings associated with human immunodeficiency virus infection. J Am Acad Dermatol 1987; 17: 746–751PubMedCrossRef Matis WL, Triana A, Shapiro R, et al. Dermatologic findings associated with human immunodeficiency virus infection. J Am Acad Dermatol 1987; 17: 746–751PubMedCrossRef
54.
Zurück zum Zitat Berger RS, Stoner MF, Hobbs ER, et al. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol 1988; 19: 298–303PubMedCrossRef Berger RS, Stoner MF, Hobbs ER, et al. Cutaneous manifestations of early human immunodeficiency virus exposure. J Am Acad Dermatol 1988; 19: 298–303PubMedCrossRef
55.
Zurück zum Zitat Mirowski GW, Hilton JF, Greenspan D, et al. Association of cutaneous and oral diseases in HIV-infected men. Oral Dis 1998; 4: 16–21PubMedCrossRef Mirowski GW, Hilton JF, Greenspan D, et al. Association of cutaneous and oral diseases in HIV-infected men. Oral Dis 1998; 4: 16–21PubMedCrossRef
56.
Zurück zum Zitat Montella F, Pezzotti P, Di Sora F, et al. Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive IV drug users. Infection 1997; 25: 117–120PubMedCrossRef Montella F, Pezzotti P, Di Sora F, et al. Improving the prognostic value of CD4+ count using IgA and clinical signs in HIV-seropositive IV drug users. Infection 1997; 25: 117–120PubMedCrossRef
57.
Zurück zum Zitat Mirmirani P, Hessol NA, Maurer TA, et al. Prevalence and predictors of skin disease in the Women’s Interagency HIV Study (WIHS). J Am Acad Dermatol 2001; 44: 785–788PubMedCrossRef Mirmirani P, Hessol NA, Maurer TA, et al. Prevalence and predictors of skin disease in the Women’s Interagency HIV Study (WIHS). J Am Acad Dermatol 2001; 44: 785–788PubMedCrossRef
58.
Zurück zum Zitat Ross S, Richardson MD, Graybill JR. Association between Malassezia furfur colonization and seborrhoeic dermatitis in AIDS patients. Mycoses 1994; 37: 367–370PubMed Ross S, Richardson MD, Graybill JR. Association between Malassezia furfur colonization and seborrhoeic dermatitis in AIDS patients. Mycoses 1994; 37: 367–370PubMed
59.
Zurück zum Zitat Wikler JR, Nieboer C, Willemze R. Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. J Am Acad Dermatol 1992; 27: 37–39PubMedCrossRef Wikler JR, Nieboer C, Willemze R. Quantitative skin cultures of Pityrosporum yeasts in patients seropositive for the human immunodeficiency virus with and without seborrheic dermatitis. J Am Acad Dermatol 1992; 27: 37–39PubMedCrossRef
60.
Zurück zum Zitat Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum yeasts. Curr Top Med Mycol 1995; 6: 95–112PubMed Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum yeasts. Curr Top Med Mycol 1995; 6: 95–112PubMed
61.
Zurück zum Zitat Perniciaro C, Peters MS. Tinea faciale mimicking seborrheic dermatitis in a patient with AIDS. N Engl J Med 1986; 314: 315–316PubMedCrossRef Perniciaro C, Peters MS. Tinea faciale mimicking seborrheic dermatitis in a patient with AIDS. N Engl J Med 1986; 314: 315–316PubMedCrossRef
62.
Zurück zum Zitat Pirkhammer D, Seeber A, Honigsmann H, et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000; 143: 964–968PubMedCrossRef Pirkhammer D, Seeber A, Honigsmann H, et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000; 143: 964–968PubMedCrossRef
63.
Zurück zum Zitat Bason MM, Berger TG, Nesbitt Jr LT. Pruritic papular eruption of HIV-disease. Int J Dermatol 1993; 32: 784–789PubMedCrossRef Bason MM, Berger TG, Nesbitt Jr LT. Pruritic papular eruption of HIV-disease. Int J Dermatol 1993; 32: 784–789PubMedCrossRef
64.
Zurück zum Zitat James WD, Redfield RR, Lupton GP, et al. A papular eruption associated with human T cell lymphotropic virus type III disease. J Am Acad Dermatol 1985; 13: 563–566PubMedCrossRef James WD, Redfield RR, Lupton GP, et al. A papular eruption associated with human T cell lymphotropic virus type III disease. J Am Acad Dermatol 1985; 13: 563–566PubMedCrossRef
65.
Zurück zum Zitat Colebunders R, Mann JM, Francis H, et al. Generalized papular pruritic eruption in African patients with human immunodeficiency virus infection. AIDS 1987; 1: 117–121PubMed Colebunders R, Mann JM, Francis H, et al. Generalized papular pruritic eruption in African patients with human immunodeficiency virus infection. AIDS 1987; 1: 117–121PubMed
66.
Zurück zum Zitat Liautaud B, Pape JW, DeHovitz JA, et al. Pruritic skin lesions: a common initial presentation of acquired immunodeficiency syndrome. Arch Dermatol 1989; 125: 629–632PubMedCrossRef Liautaud B, Pape JW, DeHovitz JA, et al. Pruritic skin lesions: a common initial presentation of acquired immunodeficiency syndrome. Arch Dermatol 1989; 125: 629–632PubMedCrossRef
67.
Zurück zum Zitat Penneys NS, Nayar JK, Bernstein H, et al. Chronic pruritic eruption in patients with acquired immunodeficiency syndrome associated with increased antibody titers to mosquito salivary gland antigens. J Am Acad Dermatol 1989; 21: 421–425PubMedCrossRef Penneys NS, Nayar JK, Bernstein H, et al. Chronic pruritic eruption in patients with acquired immunodeficiency syndrome associated with increased antibody titers to mosquito salivary gland antigens. J Am Acad Dermatol 1989; 21: 421–425PubMedCrossRef
68.
Zurück zum Zitat Hevia O, Jimenez-Acosta F, Ceballos PI, et al. Pruritic papular eruption of the acquired immunodeficiency syndrome: a clinicopathologic study. J Am Acad Dermatol 1991; 24: 231–235PubMedCrossRef Hevia O, Jimenez-Acosta F, Ceballos PI, et al. Pruritic papular eruption of the acquired immunodeficiency syndrome: a clinicopathologic study. J Am Acad Dermatol 1991; 24: 231–235PubMedCrossRef
69.
Zurück zum Zitat Soeprono FF, Schinella RA. Eosinophilic pustular folliculitis in patients with acquired immunodeficiency syndrome: report of three cases. J Am Acad Dermatol 1986; 14: 1020–1022PubMedCrossRef Soeprono FF, Schinella RA. Eosinophilic pustular folliculitis in patients with acquired immunodeficiency syndrome: report of three cases. J Am Acad Dermatol 1986; 14: 1020–1022PubMedCrossRef
70.
Zurück zum Zitat Jenkins Jr D, Fisher BK, Chalvardjian A, et al. Eosinophilic pustular folliculitis in a patient with AIDS. Int J Dermatol 1988; 27: 34–35PubMedCrossRef Jenkins Jr D, Fisher BK, Chalvardjian A, et al. Eosinophilic pustular folliculitis in a patient with AIDS. Int J Dermatol 1988; 27: 34–35PubMedCrossRef
71.
Zurück zum Zitat Buchness MR, Lim HW, Hatcher VA, et al. Eosinophilic pustular folliculitis in the acquired immunodeficiency syndrome: treatment with ultraviolet B phototherapy. N Engl J Med 1988; 318: 1183–1186PubMedCrossRef Buchness MR, Lim HW, Hatcher VA, et al. Eosinophilic pustular folliculitis in the acquired immunodeficiency syndrome: treatment with ultraviolet B phototherapy. N Engl J Med 1988; 318: 1183–1186PubMedCrossRef
72.
Zurück zum Zitat Rosenthal D, LeBoit PE, Klumpp L, et al. Human immunodeficiency virus-associated eosinophilic folliculitis: a unique dermatosis associated with advanced human immunodeficiency virus infection. Arch Dermatol 1991; 127: 206–209PubMedCrossRef Rosenthal D, LeBoit PE, Klumpp L, et al. Human immunodeficiency virus-associated eosinophilic folliculitis: a unique dermatosis associated with advanced human immunodeficiency virus infection. Arch Dermatol 1991; 127: 206–209PubMedCrossRef
73.
Zurück zum Zitat McCalmont TH, Altemus D, Maurer T, et al. Eosinophilic folliculitis: the histologic spectrum. Am J Dermatopathol 1995; 17: 439–446PubMedCrossRef McCalmont TH, Altemus D, Maurer T, et al. Eosinophilic folliculitis: the histologic spectrum. Am J Dermatopathol 1995; 17: 439–446PubMedCrossRef
74.
Zurück zum Zitat Ramos H. Erupcao papular pruritica associada ao virus da imunodeficiencia humana: etiopatogenese avaliada por analise clinica, imunohistoquimica e ultraestructural. Rev Soc Bras Med Trop 1999; 32: 199–200CrossRef Ramos H. Erupcao papular pruritica associada ao virus da imunodeficiencia humana: etiopatogenese avaliada por analise clinica, imunohistoquimica e ultraestructural. Rev Soc Bras Med Trop 1999; 32: 199–200CrossRef
75.
Zurück zum Zitat Rosatelli JB, Soares FA, Roselino AM. Pruritic papular eruption of the acquired immunodeficiency syndrome: predominance of CD8+ cells. Int J Dermatol 2000; 39: 873–874PubMedCrossRef Rosatelli JB, Soares FA, Roselino AM. Pruritic papular eruption of the acquired immunodeficiency syndrome: predominance of CD8+ cells. Int J Dermatol 2000; 39: 873–874PubMedCrossRef
76.
Zurück zum Zitat Rosatelli JB, Roselino AM. Hyper-IgE, eosinophilia, and immediate cutaneous hypersensitivity to insect antigens in the pruritic papular eruption of human immunodeficiency virus. Arch Dermatol 2001; 137: 672–673PubMed Rosatelli JB, Roselino AM. Hyper-IgE, eosinophilia, and immediate cutaneous hypersensitivity to insect antigens in the pruritic papular eruption of human immunodeficiency virus. Arch Dermatol 2001; 137: 672–673PubMed
77.
Zurück zum Zitat Boonchai W, Laohasrisakul R, Manonukul J, et al. Pruritic papular eruption in HIV seropositive patients: a cutaneous marker for immunosuppression. Int J Dermatol 1999; 38: 348–350PubMedCrossRef Boonchai W, Laohasrisakul R, Manonukul J, et al. Pruritic papular eruption in HIV seropositive patients: a cutaneous marker for immunosuppression. Int J Dermatol 1999; 38: 348–350PubMedCrossRef
78.
Zurück zum Zitat Aires JM, Rosatelli JB, de Castro Figueiredo JF, et al. Cytokines in the pruritic papular eruption of HIV. Int J Dermatol 2000; 39: 903–906PubMedCrossRef Aires JM, Rosatelli JB, de Castro Figueiredo JF, et al. Cytokines in the pruritic papular eruption of HIV. Int J Dermatol 2000; 39: 903–906PubMedCrossRef
79.
Zurück zum Zitat Reis ML, Maeda S, Rosatelli JB, et al. Kininogens and kallikrein in pruritic papular eruption. Immunopharmacology 1999; 45: 115–120PubMedCrossRef Reis ML, Maeda S, Rosatelli JB, et al. Kininogens and kallikrein in pruritic papular eruption. Immunopharmacology 1999; 45: 115–120PubMedCrossRef
80.
Zurück zum Zitat Colton AS, Schachner L, Kowalczyk AP. Eosinophilic pustular folliculitis. J Am Acad Dermatol 1986; 14: 469–474PubMedCrossRef Colton AS, Schachner L, Kowalczyk AP. Eosinophilic pustular folliculitis. J Am Acad Dermatol 1986; 14: 469–474PubMedCrossRef
81.
Zurück zum Zitat Fearfield LA, Rowe A, Francis N, et al. Itchy folliculitis and human immunodeficiency virus infection: clinicopathological and immunological features, pathogenesis and treatment. Br J Dermatol 1999; 141: 3–11PubMedCrossRef Fearfield LA, Rowe A, Francis N, et al. Itchy folliculitis and human immunodeficiency virus infection: clinicopathological and immunological features, pathogenesis and treatment. Br J Dermatol 1999; 141: 3–11PubMedCrossRef
82.
Zurück zum Zitat Magro CM, Crowson AN. Necrotizing eosinophilic folliculitis as a manifestation of the atopic diathesis. Int J Dermatol 2000; 39: 672–677PubMedCrossRef Magro CM, Crowson AN. Necrotizing eosinophilic folliculitis as a manifestation of the atopic diathesis. Int J Dermatol 2000; 39: 672–677PubMedCrossRef
83.
Zurück zum Zitat Piantanida EW, Turiansky GW, Kenner JR, et al. HIV-associated eosinophilic folliculitis: diagnosis by transverse histologic sections. J Am Acad Dermatol 1998; 38: 124–126PubMedCrossRef Piantanida EW, Turiansky GW, Kenner JR, et al. HIV-associated eosinophilic folliculitis: diagnosis by transverse histologic sections. J Am Acad Dermatol 1998; 38: 124–126PubMedCrossRef
84.
Zurück zum Zitat Smith KJ, Skelton HG, Yeager J, et al. Metronidazole for eosinophilic pustular folliculitis in human immunodeficiency virus type 1-positive patients. Arch Dermatol 1995; 131: 1089–1091PubMedCrossRef Smith KJ, Skelton HG, Yeager J, et al. Metronidazole for eosinophilic pustular folliculitis in human immunodeficiency virus type 1-positive patients. Arch Dermatol 1995; 131: 1089–1091PubMedCrossRef
85.
Zurück zum Zitat Berger TG, Heon V, King C, et al. Itraconazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis. Arch Dermatol 1995; 131: 358–360PubMedCrossRef Berger TG, Heon V, King C, et al. Itraconazole therapy for human immunodeficiency virus-associated eosinophilic folliculitis. Arch Dermatol 1995; 131: 358–360PubMedCrossRef
86.
Zurück zum Zitat Otley CC, Avram MR, Johnson RA. Isotretinoin treatment of human immunodeficiency virus-associated eosinophilic folliculitis: results of an open, pilot trial. Arch Dermatol 1995; 131: 1047–1050PubMedCrossRef Otley CC, Avram MR, Johnson RA. Isotretinoin treatment of human immunodeficiency virus-associated eosinophilic folliculitis: results of an open, pilot trial. Arch Dermatol 1995; 131: 1047–1050PubMedCrossRef
87.
Zurück zum Zitat Blauvelt A, Plott RT, Spooner K, et al. Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. Arch Dermatol 1995; 131: 360–361PubMedCrossRef Blauvelt A, Plott RT, Spooner K, et al. Eosinophilic folliculitis associated with the acquired immunodeficiency syndrome responds well to permethrin. Arch Dermatol 1995; 131: 360–361PubMedCrossRef
88.
Zurück zum Zitat Mattila JO, Vornanen M, Vaara J, et al. Mycobacteria in prurigo nodularis: the cause or a consequence? J Am Acad Dermatol 1996; 34: 224–228PubMedCrossRef Mattila JO, Vornanen M, Vaara J, et al. Mycobacteria in prurigo nodularis: the cause or a consequence? J Am Acad Dermatol 1996; 34: 224–228PubMedCrossRef
89.
Zurück zum Zitat Liang Y, Marcusson JA, Jacobi HH, et al. Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J Cutan Pathol 1998; 25: 189–198PubMedCrossRef Liang Y, Marcusson JA, Jacobi HH, et al. Histamine-containing mast cells and their relationship to NGFr-immunoreactive nerves in prurigo nodularis: a reappraisal. J Cutan Pathol 1998; 25: 189–198PubMedCrossRef
90.
Zurück zum Zitat Abadia Molina F, Burrows NP, Jones RR, et al. Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis. Br J Dermatol 1992; 127: 344–351CrossRef Abadia Molina F, Burrows NP, Jones RR, et al. Increased sensory neuropeptides in nodular prurigo: a quantitative immunohistochemical analysis. Br J Dermatol 1992; 127: 344–351CrossRef
91.
Zurück zum Zitat Stander S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44: 471–478PubMedCrossRef Stander S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44: 471–478PubMedCrossRef
92.
Zurück zum Zitat Berger TG, Hoffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol 1995; 33: 837–838PubMedCrossRef Berger TG, Hoffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol 1995; 33: 837–838PubMedCrossRef
93.
Zurück zum Zitat Berger TG, Dhar A. Lichenoid photoeruptions in human immunodeficiency virus infection. Arch Dermatol 1994; 130: 609–613PubMedCrossRef Berger TG, Dhar A. Lichenoid photoeruptions in human immunodeficiency virus infection. Arch Dermatol 1994; 130: 609–613PubMedCrossRef
94.
Zurück zum Zitat Vin-Christian K, Epstein JH, Maurer TA, et al. Photosensitivity in HIV-infected individuals. J Dermatol 2000; 27: 361–369PubMed Vin-Christian K, Epstein JH, Maurer TA, et al. Photosensitivity in HIV-infected individuals. J Dermatol 2000; 27: 361–369PubMed
95.
Zurück zum Zitat Coldiron BM, Bergstresser PR. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 1989; 125: 357–361PubMedCrossRef Coldiron BM, Bergstresser PR. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 1989; 125: 357–361PubMedCrossRef
96.
Zurück zum Zitat Rowe A, Mallon E, Rosenberger P, et al. Depletion of cutaneous peptidergic innervation in HIV-associated xerosis. J Invest Dermatol 1999; 112: 284–289PubMedCrossRef Rowe A, Mallon E, Rosenberger P, et al. Depletion of cutaneous peptidergic innervation in HIV-associated xerosis. J Invest Dermatol 1999; 112: 284–289PubMedCrossRef
Metadaten
Titel
HIV-Associated Pruritus
Etiology and Management
verfasst von
Fiza Singh
Dr Donald Rudikoff
Publikationsdatum
01.03.2003
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 3/2003
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200304030-00004

Weitere Artikel der Ausgabe 3/2003

American Journal of Clinical Dermatology 3/2003 Zur Ausgabe

Leading Article

Photodynamic Therapy

Therapy in Practice

Erysipelas

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.